|Youngeun Choi, Ph.D.|
Current Position: Postdoctoral fellow, Dana-Farber Cancer Institute/Harvard Medical School; Advisor: Dipanjan Chowdhury
My project focused primarily on understanding how two related inhibitor of apoptosis proteins, cIAP1 and cIAP2, suppressed apoptosis through their distinct interactions with the effector caspases- 3 and -7.
Indra Mahajan, Ph.D.
|Madhavi Malladi, Ph.D.|
Current Position: Clinical Research Coordinator at New York Hospital - Queens
My research was primarily focused on understanding the mechanisms by which inhibitor of apoptosis (IAP) proteins and their antagonists regulate caspase activation using Drosophila a model system.
|Srinivas Malladi, Ph.D.|
Current Position: Postdoctoral fellow, Memorial Sloan-Kettering Cancer Center; Advisor: Joan Massague
My project was focused on understanding the mechanisms of caspase-9 processing and activation within the apoptosome.
|Jaekyoung Son, Ph.D.|
Current Position: Tenure-Track Assistant Professor at the University of Ulsan College of Medicine, South Korea
I investigated the intracellular mechanisms responsible for TRAIL resistance in human prostate cancer cells, with a particular focus on the role of p38 MAPKs in this process.
|Shankar Varadarajan, Ph.D.|
Current Position: Tenure-Track Research Fellow in the Institute of Translational Medicine at The University of Liverpool, UK
I worked on two different research projects; one project dealt with the role of p38 MAPKs in regulating autophagy and lysosomal biogenesis, while the other project involved TNFR1 signaling and receptor trafficking mechanisms.
|Ting-Chun Yeh, M.S, Ph.D.|
Current Position: Medical Writer, AROG Pharmaceuticals, Dallas, TX
I worked on understanding how Grim, an endogenous inhibitor of apoptosis (IAP) antagonist in Drosophila, induces IBM-independent apoptosis.
- Epigenetics and Molecular Carcinogenesis Ph.D. Program